2328-PUB: Identification by Multivariable Analysis of Predictive Factors of HbA1c Target Achievement in People with T2D Initiating Treatment with Insulin Glargine 300 U/mL (Gla-300)—REALI Pooled Database
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
2328-PUB: Identification by Multivariable Analysis of Predictive Factors of HbA1c Target Achievement in People with T2D Initiating Treatment with Insulin Glargine 300 U/mL (Gla-300)—REALI Pooled Database
Beschreibung:
<jats:p>REALI pooled database, encompassing Gla-300 studies conducted in different European countries, is a platform to identify factors contributing to glycemic control in patients with uncontrolled T2D initiated on Gla-300. A stepwise multivariable regression analysis was performed on selected demographic and baseline characteristics associated with achieving HbA1c target &lt;7.5% after 6 months of Gla-300 treatment from 8 studies (3 interventional and 5 observational). The criterion for consideration and inclusion in the model was p &lt; 0.05. Among 2558 subjects included, 48.7% reached target HbA1C &lt;7.5%, 56% were male and 37% were insulin naïve. Mean (SD) age was 64 (9.4) years and BMI was 32.2 (5.3) kg/m2. Mean (SD) baseline HbA1c was 8.5 (1) % and starting Gla-300 dose 0.29 (0.18) U/kg/day. The analyses identified baseline HbA1c as the major predictive factor associated with achievement of HbA1c target &lt;7.5%, with a nonlinear relationship, and odds were higher in the lowest baseline HbA1c value (p&lt;0.0001). Male gender (p=0.0014), being insulin naïve (p&lt;0.0001), and lower Gla-300 starting dose (p=0.0015) were also identified as potential predictors for achieving HbA1c target &lt;7.5%. These results can help clinicians to identify patients with T2D treated with Gla-300, who are likely to achieve target HbA1c &lt;7.5%.</jats:p>
<jats:p />
<jats:sec>
<jats:title>Disclosure</jats:title>
<jats:p>N. Freemantle: Advisory Panel; Self; Sanofi. Research Support; Self; Akcea Therapeutics, Allergan, AstraZeneca, Ipsen Biopharmaceuticals, Inc., Sanofi, Takeda Pharmaceutical Company Limited. Speaker's Bureau; Self; Sanofi. G. Bigot: None. M. Bonnemaire: Employee; Self; Sanofi. D. Mauricio: Advisory Panel; Self; Merck Sharp & Dohme Corp., Sanofi. Speaker's Bureau; Self; Almirall, S.A., Boehringer Ingelheim International GmbH, Lilly Diabetes, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi, Urgo Medical. R.C. Bonadonna: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Sanofi-Aventis. Speaker's Bureau; Self; Eli Lilly and Company, Sanofi-Aventis. P. Gourdy: Advisory Panel; Self; AstraZeneca. Board Member; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi-Aventis, Servier. Speaker's Bureau; Self; Abbott, Amgen Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Novo Nordisk A/S, Sanofi-Aventis, Servier. A. Ciocca: Employee; Self; Sanofi. D. Müller-Wieland: Advisory Panel; Self; Amgen Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novo Nordisk Inc., Sanofi-Aventis Deutschland GmbH. Speaker's Bureau; Self; Amgen Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Novo Nordisk Inc., Sanofi-Aventis Deutschland GmbH.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Funding</jats:title>
<jats:p>Sanofi</jats:p>
</jats:sec>